New Premises for AMGEN in BioPark
The biopharmaceutical company AMGEN was founded in 1980 as Applied Molecular Genetics by a group of young scientists. The germ cell of this company, home to which is California, is in Thousand Oaks, northwest of Los Angeles. Only five years later AMGEN achieved its first scientific breakthrough. Thanks to gene technology, it succeeded in producing a human hormone that induces the formation of red blood cells and has already helped hundreds of thousands of dialysis and cancer patients. Today AMGEN is amongst the largest biotechnology enterprises in the world with 15,000 employees and is worth 93.5 Billion US Dollars on the stock exchange (dated July 2005). In addition to haematology (blood) and oncology (cancer), the areas of nephrology (kidneys), rheumatology, metabolic disease (metabolism), endocrinology and neurology are specialty areas being researched. AMGEN operates its own research centres not only at its headquarters in California/USA, but also in Boulder (Colorado), Seattle (Washington), Cambridge (Massachusetts) and in Europe in Regensburg. AMGEN Research GmbH was founded here at BioPark in 2000. With the goal of identifying new key structures for the development of innovative medicines, foundation research is being conducted here. The identification of low molecular compounds results from so called High-Throughput-Screening (HTS). More than 10 million compounds are analysed in Regensburg each year.
For more information see: